Go to
current issue
-
Correction to Lancet Neurol 2025; 24: 279–81 Lancet Neurol. (IF 46.5) Pub Date : 2025-04-17
Schott JM. Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time? Lancet Neurol 2025; 24: 279–81—In this Comment, the analyses of 22 asymptomatic individuals has been changed to prespecified in paragraph seven. This correction has been made to the online version as of April 17, 2025.
-
AI and neurology: an ethical path to innovation Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
No Abstract
-
Carotid revascularisation for carotid stenosis Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Jan K Ho, Graeme J Hankey
No Abstract
-
Neuropathic pain: which treatment for which patient? Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Claudia Sommer
No Abstract
-
CGRP blockade and cluster headache: another step forward Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Elizabeth Leroux
No Abstract
-
Temporal and biological heterogeneity in Lewy body disease Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Afina W Lemstra, Wilma D J van de Berg
No Abstract
-
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Pamela Shaw Dame
No Abstract
-
Prioritising faster, individualised rescue treatment in status epilepticus Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Nathalia Penagos Vargas, Oscar Mauricio Espitia Segura
No Abstract
-
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Jennifer V Gettings, Fatemeh Mohammad Alizadeh Chafjiri, Tobias Loddenkemper
No Abstract
-
Neurology cannot be embedded in non-communicable disease agendas Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Matilde Leonardi, Elena Moro, Paul Boon, Kailash P Bhatia, Claudio Bassetti, Alberto Raggi
No Abstract
-
Correction to Lancet Neurol 2024; 23: 500–10 Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Wisch JK, McKay NS, Boerwinkle AH, et al. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol 2024; 23: 500–10—In this Article, the colours in the key for parts D, E, and F of figure 3 have been swapped, and the labels for the vertical lines in figure 3D have been swapped. These corrections have been made to the
-
Correction to Lancet Neurol 2025; 24: 290 Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Drouin E, Tatu L, Hautecoeur P. Augusta Dejerine-Klumpke, a neurologist ahead of her time. Lancet Neurol 2025; 24: 290—In this Focal Point, the spelling of author Patrick Hautecoeur's name was incorrect. This correction has been made to the online version as of April 16, 2025.
-
Margaret Pericak-Vance: a force of nature in human genetics Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Jules Morgan
No Abstract
-
-
-
Would you want to know if you had Alzheimer's disease? Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Peter Ranscombe
No Abstract
-
Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Simone J A Donners, Twan J van Velzen, Suk Fun Cheng, John Gregson, Audinga-Dea Hazewinkel, Francesca B Pizzini, Bart J Emmer, Robert Simister, Toby Richards, Philippe A Lyrer, Marina Maurer, Gemma Smith, Gareth Tervit, Laurine van der Steen, Gwynedd E Pickett, Gordon Gubitz, Bob Roozenbeek, Maaike Scheele, John M Bamford, M Eline Kooi, Leo H Bonati
BackgroundCarotid revascularisation, comprising either carotid endarterectomy or stenting, is offered to patients with carotid stenosis to prevent stroke based on the results of randomised trials conducted more than 30 years ago. Since then, medical therapy for stroke prevention has improved. We aimed to assess whether patients with asymptomatic and symptomatic carotid stenosis with a low or intermediate
-
Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Nadia Soliman, Xavier Moisset, Michael C Ferraro, Daniel Ciampi de Andrade, Ralf Baron, Joletta Belton, David L H Bennett, Margarita Calvo, Patrick Dougherty, Ian Gilron, Aki J Hietaharju, Koichi Hosomi, Peter R Kamerman, Harriet Kemp, Elena K Enax-Krumova, Ewan McNicol, Theodore J Price, Srinivasa N Raja, Andrew S C Rice, Blair H Smith, Mohammad D Zunaid
BackgroundThere remains a substantial unmet need for effective and safe treatments for neuropathic pain. The Neuropathic Pain Special Interest Group aimed to update treatment recommendations, published in 2015, on the basis of new evidence from randomised controlled trials, emerging neuromodulation techniques, and advances in evidence synthesis. MethodsFor this systematic review and meta-analysis,
-
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Cristina Tassorelli, Rigmor H Jensen, Peter J Goadsby, Andrew C Charles, Stewart J Tepper, Agneta Henriette Snoer, Mette Krog Josiassen, Christine Borgen Linander, Anders Ettrup, Bjørn Sperling, Neli Boneva
BackgroundChronic cluster headache is an uncommon but highly debilitating primary headache disorder characterised by excruciating head pain recurring in daily attacks and without remission periods longer than 3 months. Treatment is challenging due to the few strategies available. Eptinezumab, approved for migraine prevention, is a humanised monoclonal antibody that targets calcitonin gene-related peptide
-
Biological effects of pathologies in Lewy body diseases: why timing matters Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Elie Matar, Glenda M Halliday
The emergence of promising biomarkers of α-synuclein Lewy pathology has led to new biological definitions and staging systems for Parkinson's disease and dementia with Lewy bodies. These research frameworks aim to enhance patient selection for studies of biomarkers and disease-modifying therapies. Building on approaches developed for Alzheimer's disease, these new frameworks focus on hallmark neuropathological
-
Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16 Rubika Balendra, Jemeen Sreedharan, Martina Hallegger, Raphaëlle Luisier, Hilal A Lashuel, Jenna M Gregory, Rickie Patani
Mutations in the TARDBP gene, which encodes the TDP-43 protein, account for only 3–5% of familial cases of amyotrophic lateral sclerosis and less than 1% of cases that are apparently idiopathic. However, the discovery of neuronal inclusions of TDP-43 as the neuropathological hallmark in the majority of cases of amyotrophic lateral sclerosis has transformed our understanding of the pathomechanisms underlying
-
Rehabilitation drives post-stroke motor recovery Lancet Neurol. (IF 46.5) Pub Date : 2025-03-26 Teresa J Kimberley, Ela B Plow
No Abstract
-
Fraud, arrogance, and tragedy: the case of Doctored Lancet Neurol. (IF 46.5) Pub Date : 2025-03-26 John Hardy
No Abstract
-
Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trial Lancet Neurol. (IF 46.5) Pub Date : 2025-03-26 Prof Gottfried Schlaug MD, Christy Cassarly PhD, Jody A Feld PhD, Prof Steve L Wolf PhD, Veronica T Rowe PhD, Prof Stacy Fritz PhD, Pratik Y Chhatbar PhD, Anant Shinde PhD, Zemin Su MAS, Prof Joseph P Broderick MD, Prof Richard Zorowitz MD, Oluwole Awosika MD, Prof Dylan Edwards PhD, Chen Lin MD, Prof Gerard E Franciso MD, Prof George F Wittenberg MD, Prof Svetlana Pundik MD, Prof Christopher Gregory
Motor impairments contribute substantially to long-term disability following stroke. Studies of transcranial direct current stimulation (tDCS), combined with various rehabilitation therapies, have shown promising results in reducing motor impairment. We aimed to evaluate the safety and efficacy of three doses of tDCS in combination with modified constraint-induced movement therapy (mCIMT) in people
-
Correction to Lancet Neurol 2024; 23: 1013–24 Lancet Neurol. (IF 46.5) Pub Date : 2025-03-25
Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2024; 23: 1013–24—In this Article, corrections have been made to definitions of safety populations in tables 1 and 3,
-
Advancing policies for rare diseases in Europe Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 The Lancet Neurology
No Abstract
-
Pharmacological therapy for cerebral cavernous malformations Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Rustam Al-Shahi Salman, Michael J Thrippleton
No Abstract
-
Thrombolysis before endovascular treatment of tandem lesions Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Bertrand Lapergue, Benjamin Gory
No Abstract
-
Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time? Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Jonathan M Schott
No Abstract
-
SARS-CoV-2 infection in people with multiple sclerosis Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Kathryn C Fitzgerald
No Abstract
-
Uncontrolled CAG expansion in neurons susceptible to Huntington's disease Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Alexandra Durr
No Abstract
-
The Genetic Epidemiology of Parkinson's Disease view Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Matthew J Farrer, GEoPD, Rosanna Asselta, Jean-Christophe Corvol, David Crosiers, Alexis Elbaz, Matthew J. Farrer, Alessio Di Fonzo, Nobutaka Hattori, Beomseok Jeon, Rejko Krüger, George Mellick, Katerina Markopoulou, Manu Sharma, Karin Wirdefeldt
No Abstract
-
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Shen-Yang Lim, all the authors, Ai Huey Tan, Azlina Ahmad-Annuar, Njideka Ulunma Okubadejo, Katja Lohmann, Huw R Morris, Tzi Shin Toh, Yi Wen Tay, Lara M Lange, Sara Bandres-Ciga, Ignacio Mata, Jia Nee Foo, Esther Sammler, Joshua Chin Ern Ooi, Alastair J Noyce, Natascha Bahr, Wei Luo, Rajeev Ojha, Andrew B Singleton, Cornelis Blauwendraat, Christine Klein
No Abstract
-
Raising awareness of degenerative cervical myelopathy Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Jay John Wardropper, Andreas K Demetriades, David B Anderson
No Abstract
-
Paediatric neurology in Ukraine: a call for help Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Alla Nechai, Oxana Nazar, Kevin Rostasy, Sameer M Zuberi, Dana Craiu, Anna Jansen, Coriene E Catsman-Berrevoets
No Abstract
-
Advocating for increased awareness and research on Down syndrome Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Marie-Claude Potier, Trisomy 21 Research Society executive board, Pierce Jonathan, Hilgenkamp Thessa, Stagni Fiorenza, Emili Marco, Wiseman Frances, Ropper Randall, Carmona-Iragui María, Rebillat Anne-Sophie, Barone Eugenio, Perluigi Marzia, Skotko Brian, Zaman Shahid, Sullivan Kelly, Rozen Esteban, Granholm-Bentley Ann-Charlotte, Bartesaghi Renata, Mobley William, Delabar Jean-Maurice, Dierssen Mara
No Abstract
-
-
Augusta Dejerine-Klumpke, a neurologist ahead of her time Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Emmanuel Drouin, Laurent Tatu, Patrick Hautecoeur
No Abstract
-
An operational measurement of brain health: the ABCDS framework Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Abolfazl Avan, Robert Andersen, Neil Andersson, Stephanie J Frisbee, Sarah Singh, Shiran Zhong, Kem A Rogers, Shawn N Whitehead, Vladimir Hachinski
No Abstract
-
Consciousness contextualised Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Robert Stirrups
No Abstract
-
The artist and the scientist join forces for rare diseases Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Jules Morgan
No Abstract
-
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Prof Issam A Awad MD, Roberto J Alcazar-Felix MD, Agnieszka Stadnik MS, Serena Kinkade BS, Aditya Jhaveri BS, Justine Lee BSN, Stephanie Hage MD, Javed Iqbal MBBS, Sean P Polster MD, Robert Shenkar PhD, Kevin Treine BA, Nichol McBee MPH, Noeleen Ostapkovich MS, Karen Lane CCRP, Prof James K Liao MD, Prof Matthew Sorrentino MD, Cornelia Lee PsyD, Prof Kelly D Flemming MD, Romuald Girard PhD, Prof Timothy
Cerebral cavernous malformations (CCMs) carry a high risk of rebleeding after symptomatic haemorrhage, with serious clinical sequelae. Atorvastatin was shown to prevent CCM growth and bleeding in animal models. We aimed to assess the safety and efficacy of atorvastatin on rebleeding in patients with CCMs after a symptomatic haemorrhage.
-
Intravenous thrombolysis before endovascular treatment versus endovascular treatment alone for patients with large vessel occlusion and carotid tandem lesions: individual participant data meta-analysis of six randomised trials Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Fabiano Cavalcante MD, Kilian Treurniet PhD, Johannes Kaesmacher PhD, Manon Kappelhof PhD, Roman Rohner MD, Prof Pengfei Yang MD, Prof Jianmin Liu MD, Kentaro Suzuki PhD, Bernard Yan MD, Theodora van Elk MD, Prof Lei Zhang MD, Maarten Uyttenboogaart PhD, Prof Wenjie Zi MD, Derraz Imad MD, Yongwei Zhang MD, Papagiannaki Chrysanthi MD, Hal Rice MBBS, Pengfei Xing MD, Prof Kazumi Kimura PhD, Prof Peter
For patients with large vessel occlusion and carotid tandem lesions, the best treatment approach is not clear. Intravenous thrombolysis in addition to endovascular treatment might increase the risk of intracranial haemorrhage and decrease effectiveness in this cohort, particularly for patients receiving acute carotid stenting. In an individual participant data meta-analysis of six randomised controlled
-
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Prof Randall J Bateman MD, Yan Li PhD, Prof Eric M McDade DO, Jorge J Llibre-Guerra MD, Prof David B Clifford MD, Alireza Atri MD, Susan L Mills BS, Anna M Santacruz BS, Guoqiao Wang PhD, Charlene Supnet PhD, Prof Tammie L S Benzinger MD, Brian A Gordon PhD, Laura Ibanez PhD, Gregory Klein PhD, Monika Baudler PhD, Rachelle S Doody MD, Paul Delmar PhD, Geoffrey A Kerchner MD, Tobias Bittner PhD, Jakub
Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an ongoing platform trial assessing the safety and efficacy of multiple investigational products in participants
-
Advances in diagnosis, classification, and management of pain in Parkinson's disease Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Prof Michele Tinazzi PhD, Prof Marialuisa Gandolfi PhD, Carlo Alberto Artusi PhD, Prof Kirsty Bannister PhD, Katarina Rukavina PhD, Prof Christine Brefel-Courbon PhD, Prof Daniel Ciampi de Andrade PhD, Prof Santiago Perez-Lloret PhD, Prof Veit Mylius PhD
With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than two-thirds of people with Parkinson's disease live with chronic pain, which can manifest in various stages of the disease, substantially affecting daily activities and quality of life. The Parkinson's disease Pain Classification System overcomes the limitations of previous classification
-
Epilepsy with myoclonic-atonic seizures: an update on genetic causes, nosological limits, and treatment strategies Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Prof Renzo Guerrini FRCP, Prof Ingrid Scheffer FRS, Simona Balestrini PhD
Epilepsy with myoclonic-atonic seizures is a childhood-onset epilepsy syndrome characterised by a range of seizure types, including myoclonic-atonic, atonic, myoclonic, absence, and generalised tonic-clonic seizures. The causes and outcomes of this syndrome are highly variable, with many uncertainties surrounding its classification and prognosis. Traditional antiseizure medications and the ketogenic
-
Multiple sclerosis and COVID-19: interactions and unresolved issues Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19 Ana Zabalza MD PhD, Prof Alan Thompson MD, Dalia L Rotstein MD MPH, Prof Amit Bar-Or MD, Prof Xavier Montalban MD
Serious symptomatic SARS-CoV-2 infection and COVID-19 complications are particular concerns for people with multiple sclerosis, especially those receiving immunosuppressants or immunomodulators. Studies have aimed to identify individuals with multiple sclerosis who are at high risk for SARS-CoV-2 infection, to analyse the interplay between SARS-CoV-2 and multiple sclerosis and to evaluate immunological
-
Direct oral anticoagulants for cerebral venous thrombosis Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Ana-Lucia Garcia Guarniz, Thalia S Field, Shadi Yaghi
No Abstract
-
Tom Solomon: world records, academic leadership, and emerging infections Lancet Neurol. (IF 46.5) Pub Date : 2025-02-21 Jules Morgan
No Abstract
-
A pivotal recognition of the burden of encephalitis Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19
No Abstract
-
Expanding the spectrum of type 1 IFN neuroinflammation Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Saba Jafarpour
No Abstract
-
Navigating the use of generative AI in peer review Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Laura Hart
No Abstract
-
Thank you to The Lancet Neurology's peer reviewers in 2024 Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19
No Abstract
-
The ATTeST trial in ataxia telangiectasia: some concerns Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Michèl A A P Willemsen, Nienke J H van Os, Nel Roeleveld, Corry M R Weemaes
No Abstract
-
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Biljana Horn, Maureen Roden, Dirk Thye
No Abstract
-
Amyloid-related iatrogenic atrophy of the brain: data transparency is an urgent safety priority Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Scott Ayton, Robert Howard, Madhav Thambisetty
No Abstract
-
Amyloid-related iatrogenic atrophy of the brain: data transparency is an urgent safety priority – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Christopher R S Belder, Delphine Boche, James A R Nicoll, Zane Jaunmuktane, Henrik Zetterberg, Jonathan M Schott, Frederik Barkhof, Nick C Fox
No Abstract
-
Encephalitis: a growing global threat Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Ava Easton
No Abstract
-
For brain health, one drink a day is not better than none Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Sanjula D Singh, Jasper R Senff, Christopher D Anderson, Jonathan Rosand
No Abstract
-
Call for the creation of a European Parliament Intergroup on brain health Lancet Neurol. (IF 46.5) Pub Date : 2025-02-19 Claudio L A Bassetti, Stephanie Kramer, Frédéric Destrebecq, Suzanne L Dickson
No Abstract
更新日期：2025-04-17
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号